Monitor the outcome of the director elections at the 2026 Annual Meeting, as the departure of two board members may signal a shift in corporate governance or strategy. The recent insider selling activity could indicate reduced confidence among executives, warranting further investigation.
Price Chart
Executive Summary
Avalo Therapeutics is holding its 2026 Annual Meeting to vote on the election of seven directors, approval of an amended employee stock purchase plan, and ratification of its auditor. This follows the recent announcement that two board members, Dr. Jonathan Goldman and Mitchell Chan, will not stand for re-election, signaling a potential shift in board composition.
Key Facts
- Avalo Therapeutics is holding its 2026 Annual Meeting to vote on director elections, an amended employee stock purchase plan, and auditor ratification.
- Two board members, Dr. Jonathan Goldman and Mitchell Chan, notified the company they will not stand for re-election at the 2026 Annual Meeting.
- The company's stock has seen recent insider selling activity, with four sells totaling $196K in the past 30 days.
- The company is in the pharmaceutical preparations sector and has a market cap of $324M.
Financial Impact
No material financial impact disclosed in the filing.
Risk Factors
- Potential for increased volatility around the Annual Meeting vote, especially if there is significant opposition to the proposed board nominees.
- Insider selling activity may raise concerns about insider sentiment, potentially impacting investor confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001534120-26-000023 |
| Document: 0001534120-26-000023-index-headers.html | 0001534120-26-000023 |
| Document: 0001534120-26-000023-index.html | 0001534120-26-000023 |
| Document: 0001534120-26-000023.txt | 0001534120-26-000023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access